Exopharm Limited
Exopharm Limited (EX1.AX) Stock Competitors & Peer Comparison
See (EX1.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EX1.AX | A$0.01 | +10.00% | 1.9M | -0.12 | -A$0.09 | N/A |
| CSL.AX | A$264.05 | -2.60% | 131.2B | 32.44 | A$8.35 | +1.57% |
| TLX.AX | A$20.15 | -2.56% | 7.1B | 150.36 | A$0.14 | N/A |
| MSB.AX | A$2.35 | -4.08% | 3B | -12.53 | -A$0.19 | N/A |
| NEU.AX | A$16.93 | +1.80% | 2.1B | 15.86 | A$1.09 | N/A |
| CU6.AX | A$4.46 | +3.00% | 1.4B | -27.31 | -A$0.16 | N/A |
| OPT.AX | A$0.60 | +0.00% | 738.8M | -1.28 | -A$0.47 | N/A |
| PYC.AX | A$1.21 | -5.10% | 723.2M | -11.27 | -A$0.11 | N/A |
| CUV.AX | A$12.43 | -3.12% | 650.1M | 16.84 | A$0.77 | +0.39% |
| IMM.AX | A$0.26 | -1.89% | 396.3M | -9.00 | -A$0.03 | N/A |
Stock Comparison
EX1.AX vs CSL.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, CSL.AX has a market cap of 131.2B. Regarding current trading prices, EX1.AX is priced at A$0.01, while CSL.AX trades at A$264.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas CSL.AX's P/E ratio is 32.44. In terms of profitability, EX1.AX's ROE is -1.10%, compared to CSL.AX's ROE of +0.15%. Regarding short-term risk, EX1.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check CSL.AX's competition here
EX1.AX vs TLX.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, TLX.AX has a market cap of 7.1B. Regarding current trading prices, EX1.AX is priced at A$0.01, while TLX.AX trades at A$20.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas TLX.AX's P/E ratio is 150.36. In terms of profitability, EX1.AX's ROE is -1.10%, compared to TLX.AX's ROE of +0.06%. Regarding short-term risk, EX1.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check TLX.AX's competition here
EX1.AX vs MSB.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, MSB.AX has a market cap of 3B. Regarding current trading prices, EX1.AX is priced at A$0.01, while MSB.AX trades at A$2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas MSB.AX's P/E ratio is -12.53. In terms of profitability, EX1.AX's ROE is -1.10%, compared to MSB.AX's ROE of -0.22%. Regarding short-term risk, EX1.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check MSB.AX's competition here
EX1.AX vs NEU.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, NEU.AX has a market cap of 2.1B. Regarding current trading prices, EX1.AX is priced at A$0.01, while NEU.AX trades at A$16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas NEU.AX's P/E ratio is 15.86. In terms of profitability, EX1.AX's ROE is -1.10%, compared to NEU.AX's ROE of +0.49%. Regarding short-term risk, EX1.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check NEU.AX's competition here
EX1.AX vs CU6.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, CU6.AX has a market cap of 1.4B. Regarding current trading prices, EX1.AX is priced at A$0.01, while CU6.AX trades at A$4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas CU6.AX's P/E ratio is -27.31. In terms of profitability, EX1.AX's ROE is -1.10%, compared to CU6.AX's ROE of -0.36%. Regarding short-term risk, EX1.AX is less volatile compared to CU6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check CU6.AX's competition here
EX1.AX vs OPT.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, OPT.AX has a market cap of 738.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas OPT.AX's P/E ratio is -1.28. In terms of profitability, EX1.AX's ROE is -1.10%, compared to OPT.AX's ROE of +5.43%. Regarding short-term risk, EX1.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check OPT.AX's competition here
EX1.AX vs PYC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PYC.AX has a market cap of 723.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PYC.AX trades at A$1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PYC.AX's P/E ratio is -11.27. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PYC.AX's ROE of -0.71%. Regarding short-term risk, EX1.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PYC.AX's competition here
EX1.AX vs CUV.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, CUV.AX has a market cap of 650.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while CUV.AX trades at A$12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas CUV.AX's P/E ratio is 16.84. In terms of profitability, EX1.AX's ROE is -1.10%, compared to CUV.AX's ROE of +0.18%. Regarding short-term risk, EX1.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check CUV.AX's competition here
EX1.AX vs IMM.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, IMM.AX has a market cap of 396.3M. Regarding current trading prices, EX1.AX is priced at A$0.01, while IMM.AX trades at A$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas IMM.AX's P/E ratio is -9.00. In terms of profitability, EX1.AX's ROE is -1.10%, compared to IMM.AX's ROE of -0.24%. Regarding short-term risk, EX1.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check IMM.AX's competition here
EX1.AX vs OCC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, OCC.AX has a market cap of 312.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while OCC.AX trades at A$1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas OCC.AX's P/E ratio is -63.75. In terms of profitability, EX1.AX's ROE is -1.10%, compared to OCC.AX's ROE of -0.27%. Regarding short-term risk, EX1.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check OCC.AX's competition here
EX1.AX vs BOT.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BOT.AX has a market cap of 294.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BOT.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BOT.AX's P/E ratio is -7.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BOT.AX's ROE of -0.39%. Regarding short-term risk, EX1.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check BOT.AX's competition here
EX1.AX vs DXB.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, DXB.AX has a market cap of 282.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while DXB.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas DXB.AX's P/E ratio is -11.75. In terms of profitability, EX1.AX's ROE is -1.10%, compared to DXB.AX's ROE of -1.84%. Regarding short-term risk, EX1.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check DXB.AX's competition here
EX1.AX vs RAC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, RAC.AX has a market cap of 201.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while RAC.AX trades at A$1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas RAC.AX's P/E ratio is -23.20. In terms of profitability, EX1.AX's ROE is -1.10%, compared to RAC.AX's ROE of -0.39%. Regarding short-term risk, EX1.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check RAC.AX's competition here
EX1.AX vs PAR.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PAR.AX has a market cap of 141.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PAR.AX trades at A$0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PAR.AX's P/E ratio is -7.10. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PAR.AX's ROE of -0.54%. Regarding short-term risk, EX1.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PAR.AX's competition here
EX1.AX vs ATH.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ATH.AX has a market cap of 128.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ATH.AX's P/E ratio is -1.40. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ATH.AX's ROE of -1.83%. Regarding short-term risk, EX1.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ATH.AX's competition here
EX1.AX vs ATX.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ATX.AX has a market cap of 116.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ATX.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ATX.AX's P/E ratio is -12.00. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ATX.AX's ROE of -0.51%. Regarding short-term risk, EX1.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ATX.AX's competition here
EX1.AX vs ALA.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ALA.AX has a market cap of 116.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ALA.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ALA.AX's P/E ratio is -9.80. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ALA.AX's ROE of -0.55%. Regarding short-term risk, EX1.AX is less volatile compared to ALA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ALA.AX's competition here
EX1.AX vs BIO.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BIO.AX has a market cap of 114.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BIO.AX trades at A$0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BIO.AX's P/E ratio is -52.00. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BIO.AX's ROE of +0.08%. Regarding short-term risk, EX1.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check BIO.AX's competition here
EX1.AX vs PAA.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PAA.AX's ROE of -0.87%. Regarding short-term risk, EX1.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PAA.AX's competition here
EX1.AX vs RCE.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, RCE.AX has a market cap of 111.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while RCE.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas RCE.AX's P/E ratio is -4.30. In terms of profitability, EX1.AX's ROE is -1.10%, compared to RCE.AX's ROE of +2.47%. Regarding short-term risk, EX1.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check RCE.AX's competition here
EX1.AX vs EZZ.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, EZZ.AX has a market cap of 95.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while EZZ.AX trades at A$2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas EZZ.AX's P/E ratio is 9.67. In terms of profitability, EX1.AX's ROE is -1.10%, compared to EZZ.AX's ROE of +0.40%. Regarding short-term risk, EX1.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check EZZ.AX's competition here
EX1.AX vs AGN.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, AGN.AX has a market cap of 87.4M. Regarding current trading prices, EX1.AX is priced at A$0.01, while AGN.AX trades at A$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas AGN.AX's P/E ratio is -13.60. In terms of profitability, EX1.AX's ROE is -1.10%, compared to AGN.AX's ROE of -0.39%. Regarding short-term risk, EX1.AX is less volatile compared to AGN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check AGN.AX's competition here
EX1.AX vs NSB.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, NSB.AX has a market cap of 78.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while NSB.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas NSB.AX's P/E ratio is 23.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to NSB.AX's ROE of +0.23%. Regarding short-term risk, EX1.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check NSB.AX's competition here
EX1.AX vs IMU.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, IMU.AX has a market cap of 77.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while IMU.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas IMU.AX's P/E ratio is -0.45. In terms of profitability, EX1.AX's ROE is -1.10%, compared to IMU.AX's ROE of -1.42%. Regarding short-term risk, EX1.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check IMU.AX's competition here
EX1.AX vs NYR.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, NYR.AX has a market cap of 77.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while NYR.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas NYR.AX's P/E ratio is -18.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to NYR.AX's ROE of -0.73%. Regarding short-term risk, EX1.AX is less volatile compared to NYR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check NYR.AX's competition here
EX1.AX vs ACW.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ACW.AX has a market cap of 76.3M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ACW.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ACW.AX's P/E ratio is -2.40. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ACW.AX's ROE of -0.44%. Regarding short-term risk, EX1.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ACW.AX's competition here
EX1.AX vs PIQ.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PIQ.AX has a market cap of 58.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PIQ.AX trades at A$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PIQ.AX's P/E ratio is -6.00. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PIQ.AX's ROE of -0.96%. Regarding short-term risk, EX1.AX is less volatile compared to PIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PIQ.AX's competition here
EX1.AX vs RAD.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, RAD.AX has a market cap of 54.4M. Regarding current trading prices, EX1.AX is priced at A$0.01, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas RAD.AX's P/E ratio is -0.38. In terms of profitability, EX1.AX's ROE is -1.10%, compared to RAD.AX's ROE of -1.03%. Regarding short-term risk, EX1.AX and RAD.AX have similar daily volatility (0.00).Check RAD.AX's competition here
EX1.AX vs ADO.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ADO.AX has a market cap of 51.4M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ADO.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ADO.AX's P/E ratio is -1.90. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ADO.AX's ROE of -1.34%. Regarding short-term risk, EX1.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ADO.AX's competition here
EX1.AX vs ILA.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ILA.AX has a market cap of 42M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ILA.AX trades at A$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ILA.AX's P/E ratio is -5.67. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ILA.AX's ROE of -1.20%. Regarding short-term risk, EX1.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check ILA.AX's competition here
EX1.AX vs SPL.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, SPL.AX has a market cap of 41.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while SPL.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas SPL.AX's P/E ratio is -3.33. In terms of profitability, EX1.AX's ROE is -1.10%, compared to SPL.AX's ROE of -0.49%. Regarding short-term risk, EX1.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check SPL.AX's competition here
EX1.AX vs PTX.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PTX.AX has a market cap of 37.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PTX.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PTX.AX's P/E ratio is -4.70. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PTX.AX's ROE of -0.42%. Regarding short-term risk, EX1.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PTX.AX's competition here
EX1.AX vs CYP.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, CYP.AX has a market cap of 35M. Regarding current trading prices, EX1.AX is priced at A$0.01, while CYP.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas CYP.AX's P/E ratio is -3.10. In terms of profitability, EX1.AX's ROE is -1.10%, compared to CYP.AX's ROE of -0.95%. Regarding short-term risk, EX1.AX is less volatile compared to CYP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check CYP.AX's competition here
EX1.AX vs NOX.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, NOX.AX has a market cap of 30.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while NOX.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas NOX.AX's P/E ratio is -10.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to NOX.AX's ROE of -0.47%. Regarding short-term risk, EX1.AX is less volatile compared to NOX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check NOX.AX's competition here
EX1.AX vs LCT.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, EX1.AX's ROE is -1.10%, compared to LCT.AX's ROE of -0.54%. Regarding short-term risk, EX1.AX and LCT.AX have similar daily volatility (0.00).Check LCT.AX's competition here
EX1.AX vs NC6.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, NC6.AX has a market cap of 24.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while NC6.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas NC6.AX's P/E ratio is -7.90. In terms of profitability, EX1.AX's ROE is -1.10%, compared to NC6.AX's ROE of +3.42%. Regarding short-term risk, EX1.AX is less volatile compared to NC6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check NC6.AX's competition here
EX1.AX vs BTC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BTC.AX has a market cap of 21.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BTC.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BTC.AX's P/E ratio is 6.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BTC.AX's ROE of +0.58%. Regarding short-term risk, EX1.AX is less volatile compared to BTC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check BTC.AX's competition here
EX1.AX vs KZA.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, EX1.AX's ROE is -1.10%, compared to KZA.AX's ROE of -1.33%. Regarding short-term risk, EX1.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check KZA.AX's competition here
EX1.AX vs IMC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, IMC.AX has a market cap of 16.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while IMC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas IMC.AX's P/E ratio is -2.13. In terms of profitability, EX1.AX's ROE is -1.10%, compared to IMC.AX's ROE of -0.64%. Regarding short-term risk, EX1.AX is less volatile compared to IMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check IMC.AX's competition here
EX1.AX vs AVE.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, AVE.AX has a market cap of 15.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, EX1.AX's ROE is -1.10%, compared to AVE.AX's ROE of -0.83%. Regarding short-term risk, EX1.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check AVE.AX's competition here
EX1.AX vs MDC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, EX1.AX is priced at A$0.01, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, EX1.AX's ROE is -1.10%, compared to MDC.AX's ROE of +2.75%. Regarding short-term risk, EX1.AX and MDC.AX have similar daily volatility (0.00).Check MDC.AX's competition here
EX1.AX vs TRP.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, TRP.AX has a market cap of 14.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while TRP.AX trades at A$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas TRP.AX's P/E ratio is -3.43. In terms of profitability, EX1.AX's ROE is -1.10%, compared to TRP.AX's ROE of -0.26%. Regarding short-term risk, EX1.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check TRP.AX's competition here
EX1.AX vs BNO.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BNO.AX's ROE of -0.90%. Regarding short-term risk, EX1.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check BNO.AX's competition here
EX1.AX vs CHM.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, CHM.AX has a market cap of 9.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas CHM.AX's P/E ratio is -0.15. In terms of profitability, EX1.AX's ROE is -1.10%, compared to CHM.AX's ROE of -4.24%. Regarding short-term risk, EX1.AX and CHM.AX have similar daily volatility (0.00).Check CHM.AX's competition here
EX1.AX vs MEM.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, MEM.AX has a market cap of 7.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while MEM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, EX1.AX's ROE is -1.10%, compared to MEM.AX's ROE of -0.79%. Regarding short-term risk, EX1.AX and MEM.AX have similar daily volatility (0.00).Check MEM.AX's competition here
EX1.AX vs ACR.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ACR.AX has a market cap of 6.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ACR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ACR.AX's P/E ratio is -0.80. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ACR.AX's ROE of -1.79%. Regarding short-term risk, EX1.AX and ACR.AX have similar daily volatility (0.00).Check ACR.AX's competition here
EX1.AX vs IXC.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, IXC.AX has a market cap of 6.4M. Regarding current trading prices, EX1.AX is priced at A$0.01, while IXC.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas IXC.AX's P/E ratio is -4.25. In terms of profitability, EX1.AX's ROE is -1.10%, compared to IXC.AX's ROE of +0.02%. Regarding short-term risk, EX1.AX and IXC.AX have similar daily volatility (0.00).Check IXC.AX's competition here
EX1.AX vs BGT.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BGT.AX has a market cap of 5.8M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BGT.AX's P/E ratio is -1.90. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BGT.AX's ROE of -1.15%. Regarding short-term risk, EX1.AX is less volatile compared to BGT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check BGT.AX's competition here
EX1.AX vs ZLD.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ZLD.AX has a market cap of 4.9M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ZLD.AX trades at A$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ZLD.AX's P/E ratio is -0.98. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ZLD.AX's ROE of +0.75%. Regarding short-term risk, EX1.AX and ZLD.AX have similar daily volatility (0.00).Check ZLD.AX's competition here
EX1.AX vs PAB.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, PAB.AX has a market cap of 4.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while PAB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas PAB.AX's P/E ratio is N/A. In terms of profitability, EX1.AX's ROE is -1.10%, compared to PAB.AX's ROE of -1.14%. Regarding short-term risk, EX1.AX is less volatile compared to PAB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check PAB.AX's competition here
EX1.AX vs RGS.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, EX1.AX's ROE is -1.10%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, EX1.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for EX1.AX.Check RGS.AX's competition here
EX1.AX vs VBS.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, VBS.AX has a market cap of 3.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while VBS.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas VBS.AX's P/E ratio is -1.50. In terms of profitability, EX1.AX's ROE is -1.10%, compared to VBS.AX's ROE of -2.39%. Regarding short-term risk, EX1.AX and VBS.AX have similar daily volatility (0.00).Check VBS.AX's competition here
EX1.AX vs BIT.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, BIT.AX has a market cap of 2.7M. Regarding current trading prices, EX1.AX is priced at A$0.01, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas BIT.AX's P/E ratio is -0.20. In terms of profitability, EX1.AX's ROE is -1.10%, compared to BIT.AX's ROE of -13.17%. Regarding short-term risk, EX1.AX and BIT.AX have similar daily volatility (0.00).Check BIT.AX's competition here
EX1.AX vs 1AD.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, 1AD.AX has a market cap of 2.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas 1AD.AX's P/E ratio is -0.20. In terms of profitability, EX1.AX's ROE is -1.10%, compared to 1AD.AX's ROE of -4.64%. Regarding short-term risk, EX1.AX and 1AD.AX have similar daily volatility (0.00).Check 1AD.AX's competition here
EX1.AX vs HXL.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, EX1.AX is priced at A$0.01, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, EX1.AX's ROE is -1.10%, compared to HXL.AX's ROE of -0.53%. Regarding short-term risk, EX1.AX and HXL.AX have similar daily volatility (0.00).Check HXL.AX's competition here
EX1.AX vs ANR.AX Comparison August 2025
EX1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EX1.AX stands at 1.9M. In comparison, ANR.AX has a market cap of 1.5M. Regarding current trading prices, EX1.AX is priced at A$0.01, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EX1.AX currently has a P/E ratio of -0.12, whereas ANR.AX's P/E ratio is -0.70. In terms of profitability, EX1.AX's ROE is -1.10%, compared to ANR.AX's ROE of -1.42%. Regarding short-term risk, EX1.AX and ANR.AX have similar daily volatility (0.00).Check ANR.AX's competition here